Aptorum Group Limited to Present at The LD 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference

NEW YORK–()–Regulatory News:

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Mr. Darren Lui, President and Executive Director of Aptorum Group, and Dr. Herman Weiss, CEO and Executive Director of Claves Life Sciences Limited and Senior Medical Advisor of Aptorum Group, will present at the LD 500 investor conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference in September. To RSVP for the virtual conferences, please click through: https://www.ldmicro.com/events and https://hcwevents.com/

The LD 500 Virtual Conference

Date: Tuesday, September 1, 2020

Time: 9:20 AM Eastern Time (6:20 AM Pacific Time)

To book 1-on-1 investor meetings with Aptorum Group, please register for the virtual event here: https://ld-micro-conference.events.issuerdirect.com/signup

If you can’t attend the live presentation, the Company’s presentation webcast will be available on the conference event platform under the “Schedule” tab at https://ld-micro-conference.events.issuerdirect.com/presenting-companies

H.C. Wainwright 22nd Annual Global Life Sciences Conference

Date: Tuesday, September 15, 2020

Time: 9:30 AM Eastern Time (6:30 AM Pacific Time)

To book 1-on-1 investor meetings with Aptorum Group, please register for the virtual event here: https://www.meetmax.com/sched/event_61861/investor_login.html.

About Aptorum Group

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle current unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan oncology diseases, infectious diseases, metabolic diseases and woman’s health, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets marketed under the brand name NativusWell®.

For more information about Aptorum Group, please visit our website: www.aptorumgroup.com

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.

These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future and the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and could be materially different from those described herein.

Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided ”as is” without any representation or warranty of any kind.


About the Author: Biotech Today

You might like